Johnson & Johnson announced that it is starting the Phase 1 of first-in-human clinical trial of a preventive Ebola vaccine on Tuesday. The vaccine is developed at Janssen Pharmaceutical Companies and trial will be headed by the Oxford Vaccine Group.
By January's end, enrollment will be completed. First volunteers have already received the first vaccine dose. The vaccine uses a booster developed by Denmark's Bavarian Nordic. The Oxford Vaccine Group has asked 72 healthy adult volunteers from the Oxfordshire area to be part of the phase 1 trial.
Also read: Champions League round of 16 draw 2016-17
15:17 Yankees to retire Derek Jeter’s No. 2 on May 1415
00:29 Unlocked HTC One M9 gets updated to Android 7.0 Nougat today14 4
16:17 Why analysts think Kevin Johnson is the right replacement for Starbucks CEO Howard Schultz13
12:43 Outgoing Starbucks CEO Howard Schultz: Kevin Johnson better prepared to be CEO15